Role of Commensal Flora in the Development of Bacteremia and Fungemia in Cancer And Stem Cell Transplant Patients

Study ID
STU 082012-063

Cancer Related
Yes

Healthy Volunteers
No

Study Sites

Contact
Niechelle Loyd
214-456-3359
niechelle.loyd@childrens.com

Principal Investigator
Andrew Koh

Summary

Pediatric leukemia patients admitted for 1) new diagnosis, 2) chemotherapy, or 3) fever and neutropenia will be identified. HSCT patients admitted for 1) stem cell transplant or 2) fever will be identified. Data will be collected from the computerized database as detailed below. Stool (~200 mg) will be collected at the time of 1) admission; 2) every 7 days thereafter; 3) documented eMBSi 4) discharge. Bacterial and fungal gDna will be isolated from fecal specimens for deep sequencing. if an enrolled patient develops an eMBSi, the stool sample will also be processed in order to isolate the same eMBSi microbial isolate from the stool. The microbial pathogens recovered from the stool will then be tested using microbe specific qPCR, antibiotic sensitivity, genetic fingerprinting, and/or protein signature testing.

Participant Eligibility

1) Pediatric patients diagnosed with leukemia (acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), juvenile myelomonocytic leukemia (JMML), and chronic mylogenous leukemia (CML) who are admitted for cancer treatment OR for fever and neutropenia

2) Pediatric patients undergoing autologous or allogeneic hematopoietic stem cell tranplantation (HSCT) OR who have received HSCT and are being readmitted for fever